Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  gene therapy
Results 1-25 of 35 for your search:
Start Over
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TG4010.14/TIME, NCI-2013-00825, 8559, TG4010.14/TIME, 8559, NCT01383148
Phase 3 Study of ProstAtak™ Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PrTK03, NCI-2012-01912, NCT01436968
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
Phase: Phase III
Type: Treatment
Age: 18 to 85
Trial IDs: ALN-TTR02-004, NCI-2014-01434, 2013-002987-17, NCT01960348
Genetically Modified T Cells, Aldesleukin, and Combination Chemotherapy in Treating Patients with Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0013, NCI-2013-01468, 1004-1036, 110013, 344344, P10648, RD-10-IV-02, NCT01218867
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0432, NCI-2011-03444, NCT01455389
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADP-0011-001, NCI-2015-00728, 230612, NCT01567891
CT Antigen TCR-Engineered T Cells for Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: ADP-0011-002, NCI-2014-00096, NCT01892293
Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 50 to 80
Trial IDs: MTG-REIC-PC003, NCI-2014-01003, NCT01931046
Genetically Engineered Lymphocytes and Aldesleukin after Cyclophosphamide and Fludarabine Phosphate in Treating Patients with Metastatic or Locally Advanced Refractory/Recurrent Cancer That Expresses MAGE-A3
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 14-C-0110, NCI-2014-02496, 1402-1293, 338101, P131467, RD-14-III-03, NCT02153905
T-cell Receptor Gene Therapy Targeting HPV-16 E6 in Treating Patients with Metastatic, Recurrent, or Refractory HPV-Related Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 15-C-0005, NCI-2014-02319, 1407-1331, 337514, P141607, RD-14-VIII-09, NCT02280811
Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 76
Trial IDs: PaTK02, NCI-2015-00859, NCT02446093
Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Stage IV Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J0947, NCI-2010-02004, NA_00024527, JHOC-J0947, GENENTECH-JHOC-J0947, NCT00971737
Vaccine Therapy after Donor Stem Cell Transplant in Treating Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-217, NCI-2013-00286, NCT01773395
Immunotherapy Study for Patients With Stage IV Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NLG0304, NCI-2014-00700, 1303-1217, NCT02054520
Genetically Engineered NY-ESO-1-Specific T Lymphocytes and Aldesleukin in Treating Patients with NY-ESO-1 Expressing Metastatic Melanoma
Phase: Phase II
Type: Treatment
Age: 18 to 66
Trial IDs: 14-C-0058, NCI-2014-02466, 1312-1281, 140058, P131320, RD-13-XII-15, NCT02062359
Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PNT2258-03-DLBCL (Wolverine), NCI-2014-02143, NCT02226965
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SGT53-02-2, NCI-2015-00561, NCT02340156
Vaccinia Virus in Treating Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: 06-041, NCI-2011-02461, NCT00574977
Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0252, NCI-2009-01195, 06-009392, MAYO-MC0252, NCT00788307
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Phase: Phase I
Type: Treatment
Age: 3 to 22
Trial IDs: 07-098, NCI-2015-00672, NCT00634231
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Genetically-Modified Donor T Cells in Treating Patients with Relapsed B-Cell Malignancies after Donor Stem Cell Transplant
Phase: Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: 10-C-0054, NCI-2013-01457, 100054, P09556, NCT01087294
Genetically Modified T-Cells in Treating Patients With Glioblastoma Multiform
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: HERT-GBM, NCI-2012-00633, H-24487, NCT01109095
Gene-Modified T Cells in Treating Patients with Metastatic Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-036, NCI-2010-01408, NCT01140373
Start Over